Coronary artery disease (CAD) and its consequences remain the single largest cause of death in the United States. Epidemiologic studies have established the key roles of several risk factors for coronary artery disease (CAD). However, there is significant overlap in extent and severity of established CAD risk factors between disease and control populations. This suggests that the disease in the general population cannot be accounted for by these risk factors alone and leaves open the question of how to identify novel risk factors. Through a series of studies, we recently identified a loss of function mutation in the Wnt co-receptor LRP6 (LRP6R611C) that underlies a Mendelian form of coronary artery disease, diabetes and metabolic syndrome. The characterization of the mutation has shown that it impairs ligand binding, reduces LRP6 phosphorylation and nuclear beta-catenin localization in response to Wnt stimulation, and subsequently impairs downstream Wnt signaling. Since our initial discovery, impaired Wnt signaling has shown to be a risk factor for CAD in multiple clinical and experimental studies. Discovery of this disease gene and its link to altered canonical Wnt signaling has provided an exceptional opportunity for identification of novel disease pathways. Through homologous recombination, we have generated mice with the LRP6R611C mutation. LRP6R611C mice replicate most human phenotypes, including arterial intimal hyperplasia on high fat diet and develop extremely diffuse and proliferative CAD when they are homozygote for the disease allele. We propose ( 1) to determine the origin of the neointimal cell (2) to examine the role of """"""""canonical"""""""" Wnt-catenin signaling in neointima formation and (3) to assess the contribution of bone marrow derived cells (BMD) to neointima formation, by fate mapping, genetic rescue and generation of bone marrow chimeras.
Abstract: Coronary artery disease is the major cause of mortality We have identified a mutation in a gene called LRP6, which causes early coronary artery disease. We propose to study the mechanism of these diseases in a mouse model of this mutation in order to identify novel drug targets.
|Arscott, Patricia; Caleshu, Colleen; Kotzer, Katrina et al. (2016) A Case for Inclusion of Genetic Counselors in Cardiac Care. Cardiol Rev 24:49-55|
|Li, Na; Subrahmanyan, Lakshman; Smith, Emily et al. (2016) Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus. Am J Hum Genet 98:1082-91|
|Ziki, Maen D Abou; Mani, Arya (2016) Metabolic syndrome: genetic insights into disease pathogenesis. Curr Opin Lipidol 27:162-71|
|Mani, Arya (2016) Albuminuria in Hypertensive Patients: Where the Choice of Antihypertensive Medications Matters:: Commentary on ""Several Conventional Risk Markers Suggesting Presence of Albuminuria Are Weak Among Rural Africans With Hypertension"". J Clin Hypertens (Greenwich) 18:31-2|
|Li, Na; Subrahmanyan, Lakshman; Smith, Emily et al. (2016) Mutations in the Histone Modifier PRDM6 Are Associated with Isolated Nonsyndromic Patent Ductus Arteriosus. Am J Hum Genet 99:1000|
|Wang, Shuxia; Song, Kangxing; Srivastava, Roshni et al. (2015) Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. FASEB J 29:3436-45|
|Hannah-Shmouni, Fady; Seidelmann, Sara B; Sirrs, Sandra et al. (2015) The Genetic Challenges and Opportunities in Advanced Heart Failure. Can J Cardiol 31:1338-50|
|Srivastava, Roshni; Zhang, Jiasheng; Go, Gwang-Woong et al. (2015) Impaired LRP6-TCF7L2 Activity Enhances Smooth Muscle Cell Plasticity and Causes Coronary Artery Disease. Cell Rep 13:746-59|
|Martin, Kathleen A; Mani, Mitra V; Mani, Arya (2015) New targets to treat obesity and the metabolic syndrome. Eur J Pharmacol 763:64-74|
|Keramati, Ali R; Fathzadeh, Mohsen; Go, Gwang-Woong et al. (2014) A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med 370:1909-19|
Showing the most recent 10 out of 13 publications